| Drug Name |
Mecasermin |
| Drug ID |
BADD_D01358 |
| Description |
Mecasermin contains recombinant-DNA-engineered human insulin-like growth factor-1 (rhIGF-1)[FDA Label]. IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges and a molecular weight of 7649 daltons. The amino acid sequence of the product is identical to that of endogenous human IGF-1. The rhIGF-1 protein is synthesized in bacteria (E. coli) that have been modified by the addition of the gene for human IGF-1. |
| Indications and Usage |
For the long-term treatment of growth failure in pediatric patients with Primary IGFD or with GH gene deletion who have developed neutralizing antibodies to GH [A2322]. It is not indicated to treat Secondary IGFD resulting from GH deficiency, malnutrition, hypothyroidism or other causes; it is not a substitute for GH therapy. |
| Marketing Status |
approved; investigational |
| ATC Code |
H01AC03 |
| DrugBank ID |
DB01277
|
| KEGG ID |
D03297
|
| MeSH ID |
C000604197
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0F3JT
|
| NDC Product Code |
15054-1040; 69443-510; 49187-0810; 69443-512 |
| UNII |
7GR9I2683O
|
| Synonyms |
mecasermin | mescamerin recombinant | CEP-151 | Increlex |
